Keywords
How to Cite
Abstract
Pleural effusion accompanying malignant lesions of the pleura is often a marker of the spread of the tumour process. Effusion is associated with the limited opportunities of the local control and as a consequence with poor long-term results. The morphological, immunohistochemical, and molecular features of the tumour are important prognostic and predictive factors that largely determine the therapeutic tactics. Clinical guidelines in the vast majority of cases with pleural effusion indicate that the treatment goal is palliation. The main goal in these patients is to reduce symptoms and improve quality of life. Asymptomatic pleural effusion does not require treatment. Thoracentesis or symptomatic drainage provides immediate relief. With low exudate volumes and accumulation rate, rare relapses and the expected response from the systemic treatment, or, on the other hand, a short expectancy of life, it is possible to limit the management of such cases with symptomatic drainage only. In selected individuals with pleural effusion minimally invasive or surgical interventions are also recommended. These include the installation of indwelling pleural catheters, the implementation of various pleurodesis techniques. In selected subgroups, the local control can reach 87-96%. The introduction of modern surgical techniques for pleural procedures has reduced the incidence of adverse events rate to 2,7-4%. There is no doubt that it is necessary to improve algorithms and search for alternate ve solutions, including those based on combined approaches to the treatment of patients with malignant neoplastic lesions of the pleura.
References
Арсеньев А.И., Нефедов А.О., Левченко Е.В. и соавт. Оптимизация методов лечения хирургических осложнений при раке лёгкого. Вопросы онкологии. 2012; 58(5):674-679.
Левченко Е.В., Мамонтов О.Ю., Сенчик К.Ю. и др. Гипертермическая химиоперфузия плевральной полости в комбинированном лечении злокачественной мезотелиомы плевры. Вопросы онкологии. 2014;4:482-485.
Arrieta O., Escamilla-López I., Lyra-González I. et al. Radical aggressive treatment among non-small cell lung cancer patients with malignant pleural effusion without extra-thoracic disease. J. Thorac. Dis. 2019;11(2):595-601.
Bibby A.C., Dorn P., Psallidas I. et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur. Respir. J. 2018;52: 1800349. https://doi.org/10.1183/13993003.00349-2018.
Brims F.J., Meniawy T.M., Duffus I. et al. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. J. Thorac. Oncol. 2016; 11: 573-582.
Chen J., Li Z., Xu N. et al. Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer. Int. J. Clin. Exp. Med. 2015; 8(10):18945–18953.
Chiang C.L., Wang L.C., Ho H.L. et al. Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. Oncotarget. 2017; 9(4):5435-5444.
Clive A.O.J., Bhatnagar R., Preston N.J. et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst. Rev. 2016; 5:CD010529.
Dai C., Ren Y., Xie D. et al. Does lymph node metastasis have a negative prognostic impact in patients with NSCLC and M1a disease? J. Thorac. Oncol. 2016;11(10):1745-1754.
Davies H.E., Mishra E.K., Kahan B.C. et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307: 2383-2389.
Feller-Kopman D.J., Reddy C.B. et al. On behalf of the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018; 198(7):839–849.
Guinde J., Georges S., Bourinet V. et al. Recent developments in pleurodesis for malignant pleural disease. Clin. Respir. J. 2018;12:2463–2468.
Ichinose Y., Tsuchiya R., Koike T. et al. Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease. Lung Cancer. 2001;32(1):55-60.
Koegelenberg C.F.N., Shaw J.A., Irusen E.M., Gary Lee Y. C. Contemporary best practice in the management of malignant pleural effusion. Ther. Adv. Respir. Dis. 2018;12:1–13.
Lan R.S., Lo S.K., Chuang M.L. et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann. Intern. Med. 1997;126:768–774.
Li H., Sun Z., Yang F. et al. Primary tumour resection in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): a population-based study. Eur. J. Cardiothorac. Surg. 2019;55(6):1121-1129.
Mercaldi C.J., Lanes S.F. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest. 2013;143:532–538.
Ost D.E., Niu J., Zhao H. et al. Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions. Chest. 2018;153(2):438-452.
Porcel J.M., Lui M.M.S., Lerner A.D. et al. Comparing approaches to the management of malignant pleural effusions. Expert Review of Respiratory Medicine. 2017. DOI: 10.1080/17476348.2017.1300532.
Ren Y., Dai C., Shen J. et al. The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected. Oncotarget. 2016;7(18):26856-26865.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021